catalyst biosciences
Targacept and Catalyst sign $100 million deal
March 9, 2015Research and Development, Sales and Marketing CB 813d, PF-05280602, Targecept, blood disorder, catalyst biosciences
Targacept and Catalyst Biosciences have signed a merger agreement which will see them develop new treatment options for patients with …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
